The last time I wrote, I was having a hard time finding value in the high-quality dividend growth segment that I invest in. I'm happy to report that this time around, there are several stocks that potentially appear toWhy DividendRodeo? It's not the wild ride that investing sometimes provides that I'm addicted to, it's that rush that an ever-increasing flow of passive income provides. I do not have a financial background - my background is actually engineering - but I have been a self-directed investor for ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion. It's a lot but still less than one-third of the amount soaked up by American hospitals. It might not feel like it when you pay the bill, but prescription drugs give healthcare systems a tremendous return on their investment. With this in mind, it's no wonder billionaires are buying up shares of one of America's largest pharma ...

Pfizer Inc. (NYSE:PFE) Jefferies London Healthcare Conference November 20, 2024 4:00 AM ET Company Participants Dave Denton - CFO Andrew Baum - Chief Strategy and Innovation Officer, EVP Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good to start. All right. Good morning, everyone. This is day two of our London Healthcare Conference. My name is Akash Tewari. I am a pharma and biotech analyst here at Jefferies. I hope you all enjoyed day one. It was a little rainy, but still fun. I have ...

In my previous and first article about Pfizer Inc. (NYSE: PFE ), I argued that the stock could be a bargain. In the meantime, the stock increased a little bit, but especially in the last few days, it declined again and is now tradingMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitali ...

Pfizer (PFE) announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients.With this nod, the once-weekly Hympavzi gets approved for routine prophylaxis (RP) to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B, without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). Following this approval, Hympavzi became the first hemophilia medicine approved in the Unite ...

Collecting an above-average dividend payment can sometimes come with risks. High-yielding stocks can be due for cuts to their payouts if a company's underlying financials aren't strong enough to support its dividend payments. But that doesn't mean all high-yielding stocks are dangerous investments.Two good examples of stocks that pay more than 6% and can still be ideal long-term options for retirees are Pfizer (PFE -0.64%) and Verizon Communications (VZ 0.69%). Although their yields are high, these stocks a ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (LLY 0.35%) and Pfizer (PFE 0.96%).When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine. It ultimately raked in billions of dollars in sales for the first approved COVID-19 vaccine. Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid.Eli Lilly now ranks as the largest drugmaker in the world based on market cap. Its remarkable rise h ...

In a previous article on Seeking Alpha, I presented you with 10 companies that I consider to be attractive investment options for this month of November 2024.I specialize in constructing investment portfolios aimed at generating additional income through dividends. My focus lies on identifying companies with significant competitive advantages and strong financials that can provide you with an attractive Dividend Yield and Dividend Growth, thus enabling you to augment your dividend income annually. By combin ...

On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene.Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart DiseaseThe OLE study involves 330 par ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible Trump-era tariffs could complicate the Fed's plans, several blue-chip dividend powerhouses like AT&T and Altria have been outperforming the S&P 500 this year.MO data by YChartsTwo high-yield stocks keep drawing my investment dollars in this market. Here's why these two high-yield dividend stocks deserve a closer look from income and value investors with a long-term outlook. Big pharma' ...